



## Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference

November 21, 2018

BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield, Chief Executive Officer of Zafgen, Inc. will present a company overview at the 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 1:00 p.m. ET.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website ([www.zafgen.com](http://www.zafgen.com)) for 90 days following the conclusion of the live event.

### About Zafgen

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases. The Company's lead product candidate, ZGN-1061, a MetAP2 inhibitor for difficult-to-control type 2 diabetes, has successfully completed the initial part of a Phase 2 clinical trial. Learn more at [www.zafgen.com](http://www.zafgen.com).

### Media/Investor Relations Contacts:

Zafgen, Inc.  
Patricia Allen  
Chief Financial Officer  
617-648-9792

*Media*  
Krystle Gibbs  
Ten Bridge Communications  
[krystle@tenbridgecommunications.com](mailto:krystle@tenbridgecommunications.com)  
508-479-6358

*Investors*  
John Woolford  
Westwicke Partners  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)  
443-213-0506

The Zafgen logo consists of the word "Zafgen" in a light blue, sans-serif font. A small trademark symbol (TM) is located at the top right of the letter "n".

Source: Zafgen, Inc.